Dr. Robin L. Smith, age 54, is a business leader, entrepreneur, medical doctor and philanthropist uniquely positioned to assist public companies and health care systems to advance and be successful in the rapidly evolving health care industry. She received her B.A. degree from Yale University and her M.D. degree from the Yale School of Medicine. Dr. Smith holds an M.B.A. degree from the Wharton School of Business and completed the Stanford University Directors Program. In 2019, Dr. Smith received an honorary Doctor of Science degree from Thomas Jefferson Medical College. She is a trailblazer in the fields of regenerative medicine and predictive analytics and has focused on turnarounds, M&A and disruptive innovations driving interest and growth.

She has extensive experience serving on the boards of directors and board committees, including, audit, nominating and governance, compensation and science and technology committees, of multiple public companies. She currently serves on the board of directors of Celularity Inc, a Celgene spin-out focused on cancer and regenerative medicine as well as Seelos Therapeutics (NASDAQ: SEEL). Over the last 3 years, she served as chairman of the board of directors of MYnd Analytics, Inc. (NASDAQ: MYND) and Rockwell Medical (NASDAQ: RMTI) and from July 2014 to February 2016 was a director of Signal Genetics (NASDAQ: SGNL). From 2006 until 2015, Dr. Smith was chairman and chief executive officer of the Neostem (NASDAQ: NBS), where she pioneered the company’s innovative business model combining proprietary cell therapy development with successful contract development and manufacturing organization that was sold to Hitachi at 8x the price it had been acquired. During her 9 years of tenure, the company won an array of industry awards and received business recognition including a first-place ranking in the tri-state area (two years in a row), and eleventh place nationally, on Deloitte’s Technology Fast 500, and Frost & Sullivan’s North American Cell Therapeutics Technology Innovation Leadership Award.

Dr. Smith co-authored “Cells Are the New Cure“ (2017) and “The Healing Cell: How the Greatest Revolution in Medical History Is Changing Your Life” (2013). She has also been widely recognized for her leadership in health care and as a female entrepreneur. Most recently, Dr. Smith received the Regenerative Medicine Foundation (RMF) 2019 Stem Cell and Regenerative Medicine Action Award for International Diplomacy in 2019 and the 2018 HEALinc Future Health Humanitarian Award, the Business Intelligence Group’s Woman of the Year Award in 2018 and the 2018 Gold Stevie® Award for Woman of the Year – Government or Non-Profit. In April 2016, Pope Francis awarded Dr. Smith Dame Commander with Star Pontifical Equestrian Order of Saint Sylvester Pope and Martyr. In May 2017, she was awarded the Lifetime Achievement in Healthcare and Science Award by The National Museum of Catholic Art and Library.

Dr. Smith is also active in many nonprofit organizations. In 2007, she founded the Stem for Life Foundation (SFLF), devoted to fostering global awareness of the potential for regenerative medicine to treat and cure a range of deadly diseases and debilitating medical conditions. In 2010, Dr. Smith forged a historic, first-of-its-kind partnership with the Vatican, bringing the charity’s mission to a global audience. As part of this relationship, the Vatican and SFLF create high-profile initiatives to catalyze interest and investment to reduce human suffering on a global scale. Dr. Smith has served as chairman of the board and president of SFLF since its inception and has been expanding its mission further under the Cura Foundation brand as its founder, president and chairman of the board since 2016.

Dr. Smith is a member of the board of trustees of the Alliance for Regenerative Medicine (ARM) Foundation, Unite to Prevent Cancer (UTPC) Foundation and the Alliance for Cell Therapy Now. She also serves on the board of overseers of the New York University Langone Medical Center in New York. She had previously served on the board of trustees of the New York University Langone Medical Center and was chairman of the board of directors of the New York University Hospital for Joint Diseases.

One of TV’s most respected medical journalists, Dr. Max Gomez has produced award-winning health and science segments for network stations in New York and Philadelphia. Dr. Max has reported for Dateline, Today Show and 48 Hours. He is currently the senior medical correspondent for WCBS, the flagship CBS network station in New York.

Over more than three decades, he’s earned nine Emmy Awards, three NY State Broadcaster’s Association awards and UPI’s “Best Documentary” award. In 2018, Dr. Max was recognized for his distinguished career by the National Academy of Television, Arts, and Sciences.

In addition to NYC’s ‘Excellence in Time of Crisis’ for his September 11 coverage, Dr. Max has been singled out nationally for special award recognition by the Leukemia and Lymphoma Society and The National Marfan Foundation. He was also named the American Health Foundation’s “Man of the Year”.

Dr. Max co-founded, helped organize and moderated major parts of four International Vatican Scientific Conferences beginning in 2011. These events brought together the world’s leading researchers, physicians, patients, ethicists and leaders of faith, government officials, and philanthropists who engaged in important conversations about breakthrough technologies and science as it relates to global health care.

Dr. Max is the co-author of “Cells are the New Cure – The Cutting Edge Medical Breakthroughs that are Transforming Our Health“ as well as “Our Stem Cells – The Mysteries of Life and Secrets of Healing,” and “The Prostate Health Program: A Guide to Preventing and Controlling Prostate Cancer.”

Dr. Max has served on the national board of directors for the American Heart Association, the Princeton Alumni Weekly, and Partnership for After School Education. He has chaired the national communications committees for the American Heart Association and the American Association for the Advancement of Science.

A noted moderator, speaker and media trainer, Dr. Max also mentors undergraduate journalism and medical students and physicians who are interested in medical journalism.

Dr. Max is an honors graduate of Princeton University, received his PhD in Neuroscience from the Wake Forest University School of Medicine and was an NIH postdoctoral fellow at Rockefeller University.

Mr. Steven Martin is the Managing Member and a founder of Aspire Capital Fund, LLC a Chicago-based investment fund started in 2010 which has invested over $250 million in small emerging growth companies. Aspire Capital is focused on investing in life science companies and promoting early stage clinical development of cellular therapies and regenerative medicine. Mr. Martin has thirty years of legal and financing experience and has funded or committed to fund over $1.5 billion in investments. During his career, Mr. Martin has invested in hundreds of development-stage companies and many emerging cell therapy companies catalyzing their growth.

​

In 1999, Mr. Martin also founded Fusion Capital, a private investment fund which over ten years funded small emerging growth companies with a focus on life science companies. Prior to Fusion Capital, Mr. Martin was a partner at the Chicago law firm of Katten Muchin Rosenman LLP. As an attorney, Mr. Martin represented institutional investors and companies in highly complex financings as well as venture capital and private equity transactions.

​

Mr. Martin received his Juris Doctor degree with honors from Northwestern University School of Law. Mr. Martin graduated with high honors from the University of Michigan with a Bachelors of Business Administration, concentrating in finance.